Clinical Trials Logo
  1. Home
  2. Glioblastoma, Adult
  3. NCT04116658

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma — ROSALIE  

Glioblastoma, Adult Clinical Trial

Official title:
A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

Clinical Trial Description

This is a multicenter, Phase 1b/2a, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma. EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered alone and in combination with nivolumab, and nivolumab/bevacizumab to generate preliminary safety and efficacy data in patients with progressive glioblastoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04116658
Study type Interventional
Source Enterome
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date July 13, 2020
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT03291977 - Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) Phase 3
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Terminated NCT03714334 - DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma Phase 1
Recruiting NCT03277638 - Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) Phase 1/Phase 2
Completed NCT03158389 - NCT Neuro Master Match - N²M² (NOA-20) Phase 1/Phase 2
Completed NCT03522298 - Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma Phase 2
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Completed NCT03232424 - NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma Phase 1
Completed NCT03618667 - GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification Phase 2
Recruiting NCT04128774 - Function and Composition of Regulatory B Cells in Participants With Glioblastoma
Completed NCT03744026 - Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9 Phase 1/Phase 2
Completed NCT04610229 - Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. N/A
Active, not recruiting NCT02974738 - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Phase 1
Recruiting NCT03025893 - A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Phase 2/Phase 3
Active, not recruiting NCT03181477 - Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas N/A
Completed NCT03075514 - Ketogenic Diets as an Adjuvant Therapy in Glioblastoma N/A